


## MPO-IN-1

<b>Cat. No.:</b>	HY-139915		
<b>CAS No.:</b>	2471981-21-0		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>21</sub> ClN <sub>4</sub>		
<b>Molecular Weight:</b>	400.9		
<b>Target:</b>	Glutathione Peroxidase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 200 mg/mL (498.88 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4944 mL	12.4719 mL	24.9439 mL
	5 mM	0.4989 mL	2.4944 mL	4.9888 mL
	10 mM	0.2494 mL	1.2472 mL	2.4944 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase (MPO). MPO-IN-1 has IC<sub>50</sub>s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse model of inflammation<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

2.6 μM (in plasma MPO assay); 0.12 μM (in fluorescent MPO peroxidation assay)<sup>[1]</sup>

#### In Vivo

MPO-IN-1 (compound 2) (5 and 90 mg/kg; p.o.; four hours post-Zymosan A administration) significantly reduces MPO activity in a mouse peritonitis model of acute inflammation<sup>[1]</sup>.

Mouse pharmacokinetic parameter of MPO-IN-1<sup>[1]</sup>.

Dose	V <sub>ss</sub> (L/kg)	T <sub>1/2</sub> (h)	AUC <sub>inf</sub> (nM·h) p.o.	C <sub>max</sub> (nM) p.o.	PPB (%)	F (%)

---

1/10 mg/kg i.v./p.o.	9.8	2.6	2486	502	99.6	61
-------------------------	-----	-----	------	-----	------	----

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice (mouse peritonitis model of acute inflammation) <sup>[1]</sup>
Dosage:	5 and 90 mg/kg
Administration:	p.o. (four hours post-Zymosan A administration)
Result:	Resulted in a ~50% reduction in the MPO activity at 90 mg/kg.

---

## REFERENCES

[1]. Patnaik A, et al. Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO). *Bioorg Med Chem.* 2020;28(12):115548.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA